PLENARY KEYNOTES: EMERGING MODALITIES, PLATFORMS, AND TECHNOLOGIES -
FROM mRNA TO PROTEINS
基調講演：新興のモダリティ、プラットフォーム、技術 - mRNAからタンパク質へ
Gregory Troiano, Chief Manufacturing Officer, mRNA Center of Excellence
Thanks to the rapid development of mRNA vaccines for COVID-19, the industry now has the momentum and resources to overcome many of the early CMC challenges and realize its enormous potential. This presentation will discuss the strategies in place to overcome CMC and supply chain challenges for mRNA technologies already and future innovations primed to take it to the next level.
Sophia Hober, PhD, Professor, School of Biotechnology
KTH Royal Institute of Technology
Affinity proteins are crucial for life, for building structures, performing reactions, and for signaling purposes. In life sciences and medicine, affinity proteins are used to generate knowledge, but also for diagnostic and therapeutic purposes. This talk will cover how antibodies and small affinity molecules can be used to map the human proteome, develop diagnostic tools for in vivo visualization as well as efficiently purify therapeutics based on antibodies.
Gregory Troiano, Chief Manufacturing Officer, mRNA Center of Excellence, Sanofi
Greg serves as Chief Manufacturing Officer at Translate Bio, a sanofi company, where he is responsible for strategic oversight for all aspects of cGMP CMC operations, including clinical supply, analytical testing, quality, and engineering. Prior to TBio, Greg was VP of Technology and Chief Engineer at Seer, a life sciences and health data company using nanotechnology for proteomics and biomarker discovery. Prior to Seer, Greg was VP of Nanomedicine Development and Manufacturing within Pfizer’s Pharmaceutical Sciences group, leading the development and manufacturing of novel nanoparticle drug products. Over his 20+ year career in the drug delivery field, Greg had various roles leading the pharmaceutical development of complex formulations, including numerous nano- and microparticle based systems.
Sophia Hober, PhD, Professor, School of Biotechnology, KTH Royal Institute of Technology
Sophia Hober is Professor of Molecular Biotechnology at KTH, Stockholm, Sweden. The focus of her current research group is development of predictable and robust systems for protein purification and detection by protein design and various selection methodologies. Her key scientific achievements include design and development of gene fusion systems for selective ion-exchange purification and improvements of the alkaline tolerance of protein A for industrial purification of IgG (currently a product sold by GEHealth care). Also, a novel ligand for affinity purification of proteins has been developed that display a calcium dependent binding, enabling mild elution from the column. Moreover, small bispecific protein domains with ability to strongly and selectively bind to two different proteins recently have been developed for use in diagnostic and therapeutic applications.
Stream 1: Upstream
Yves Durocher, PhD, Research Officer & Head, Mammalian Cell Expression, National Research Council Canada
Stephen Goldrick, PhD, Lecturer, Digital Bioprocess Engineering, University College London, United Kingdom
Gyun Min Lee, PhD, Professor, Cell and Developmental Biology, KAIST, Korea
Daniel G. Bracewell, PhD, Professor, Bioprocess Analysis, Biochemical Engineering, University College London, United Kingdom
Stream 2: Downstream Processing
James Reilly, Associate Director, Regeneron Pharmaceuticals Inc.
Kaihui Hu He, PhD, Laboratory Head, Microbial Platform DSP, Global CMC Development, Sanofi
Richard D. Braatz, PhD, Edwin R. Gilliland Professor, Chemical Engineering, Massachusetts Institute of Technology
Lara Fernandez-Cerezo, PhD, Associate Principal Scientist, Merck
Stream 3: Gene Therapy
James Warren, PhD, Vice President, Pharmaceutical Development, Ultragenyx Pharmaceutical
Ayda S. Mayer, PhD, Executive Director, Vector Core, REGENXBIO, Inc.
Jorge F. Haller, PhD, Director, Process & Analytical Development, Prevail Therapeutics, a Wholly Owned Subsidiary of Eli Lilly and Company
Andrea C.M. Rayat, PhD, Chair & Lecturer, Biochemical Engineering, University College London
Stream 4: Cell Therapy
Vered Caplan, CEO, Orgenesis, Inc.
Michael Delahaye, Director, Team Leader Cell Therapy Bioprocessing, AstraZeneca
Florence Salmon, PhD, Vice President, Regulatory Affairs and Preclinical Development, Ridgeline Discovery
Janet Glassford, PhD, Expert Quality Assessor, MHRA
Stream 5: Analytics and Formulation
Dan Bach Kristensen, PhD, Principal Scientist, Symphogen, Denmark
Christine Carapito, PhD, Co-Head of the BioOrganic Mass Spectrometry Laboratory, CNRS Research Director, University of Strasbourg, France
Arun Alphonse Ignatius, PhD, Director, Drug Product Sciences, Macrogenics, Inc., USA
Yunus Saricay, PhD, Specialist, Research & Development, Byondis B.V., The Netherlands